Skip to main content
. 2018 Apr 25;13(4):e0196419. doi: 10.1371/journal.pone.0196419

Fig 3. Tooth extraction increases the risk of ONJ independent of the duration of alendronate therapy.

Fig 3

The overall prevalence of ONJ in osteoporotic subjects taking oral alendronate is estimated at 0.34% (26/7625) which rises to 2.16% (11/509) after recent tooth extraction. The difference in the proportions of ONJ between subjects with and without recent tooth extraction is computed using the Fisher’s exact method. Tooth extraction is significantly associated with increased risk for ONJ among osteoporotic patients taking alendronate for 3 years or more (P = 0.012) and in those with less than 3 years of use (P <0.001), independent of drug duration. In addition, there is a greater proportion of ONJ among patients with BP duration of 3 years or more versus less than 3 years of use (0.92% versus 0.24%, P = 0.002), supporting the influence of BP duration on ONJ occurrence.